Erectile dysfunction (ED) is estimated to impact more than 150 million men this year worldwide. An understanding of the pathophysiology of ED both furthers the basic scienti®c knowledge of disease processes and provides a rational design of pharmacotherapy. At present, there are two major views regarding the pathophysiology of ED. In the ®rst hypothesis, the oxygen tensiondependent changes in the penis during erection are proposed to impact corpus cavernosum structure by inducing various cytokines, vasoactive factors and growth factors at the two different oxygen tensions (¯accidity and erection) which, in turn, alter smooth muscle metabolism and connective tissue synthesis. Decreases in the corpus cavernosum smooth muscleaconnective tissue ratio have been correlated with an increased likelihood of diffuse venous leak and a failure of the veno-occlusive mechanism in prospective patient studies. Evidence for such a hypothesis incorporates nocturnal penile tumescence and circadian changes in oxygenation as important in maintaining erectile health. The alternate hypothesis proposes that ED is the result of a metabolic imbalance between relaxatory and contractile processes within the trabecular smooth muscle such that contractile processes predominate. Based on this hypothesis, therapy can be accomplished via drugs which shift this balance towards vasodilatation, or by gene therapy approaches to supplement the de®cient components favoring smooth muscle relaxation. Both of these hypotheses predict a management strategy for ED that impacts pharmacotherapeutics. In this review of the pathophysiology of ED, each hypothesis will be examined and a synthesis devised incorporating both views. The future of research in this area as well as pharmacotherapy in ED in terms of pathophysiology is discussed including the merits and drawbacks of prophylaxis and prevention of ED.
Introduction
Designing rational pharmacotherapy for erectile dysfunction (ED) and furthering our knowledge of how the disease progresses is greatly enhanced by an understanding of the pathophysiology of ED. The primary goal in treatment is the restoration of sexual function to patients who have suffered either progressive or traumatic loss of penile erection as a consequence of other systemic diseases (eg diabetes, hypercholesterolemia, hypertension), conditions (eg depression) or injuries or surgery (eg pelvic fracture, spinal chord injury, radical retropubic prostatectomy). 1 While each of these conditions has a unique set of characteristics, one of the challenges of treating ED has been to understand the overall pathophysiology of disease. 2, 3 Of the two hypotheses we will consider, one proposes a structural basis of the condition while the other focuses on metabolic imbalances. In actual practice, neither hypothesis is exclusionary of the other and the molecular pathophysiology of ED is a synthesis of the two. In this article, we will examine the evidence for each of these hypotheses and the impact of pathophysiology on treatment design. Finally, the future of research in this area in terms of what key experiments remain will be discussed. While central and peripheral nervous system disorders can affect erectile function, only peripheral (penile) mechanisms are considered here. For central nervous system mechanisms, the reader is directed to more detailed reviews. 4, 5 (discussed in greater depth elsewhere in this series). The penis is composed of three bodies of erectile tissue a pair of corpora cavenosa and the corpus spongiosum which encompasses the urethra and terminates in the glans penis. During erection, the two corpora cavernosa ®ll with blood, transforming the penis into a`blood-®lled capacitor'. 1,6 ± 8 Anatomically, the corpora cavernosa are a unique vascular bed consisting of sinuses (the trabeculae) whose arterial blood supply arises from the resistance helicine arterioles, which in turn are supplied by the cavernosal artery. The trabeculae are drained by the emissary venules that, in turn, drain into the cavernosal veins. Penile erection is the end result of smooth muscle relaxation. As the trabecular smooth muscles relax and ®ll with blood, intracavernosal pressure and volume increase. Venoocclusion develops through stretching and compressive forces by`expandable' trabecular tissue on subtunical venules. 1,6 ± 8 The corpora cavernosa, unlike other vascular beds in the body, undergo changes in oxygen tension with function. The trabeculae, while arterially fed, have measured blood PO 2 of 20 ± 40 mmHg when the penis is in the¯accid state. 9 In contrast, during erection, the measured PO 2 of the corpora increases to arterial levels (90 ± 100 mmHg). 9 Similar changes in corporal oxygen tension have been reported by other research groups. 10, 11 Another physiological characteristic in¯uencing potency may be the phenomenon of nocturnal penile tumescence (NPT). First reported by Halverson in infants, 13 NPT episodes have been observed in nearterm fetuses with 1 ± 3 episodesah lasting 7 ± 15 min each. 15 In adult males, NPT episodes are up to half an hour in length, coincident with rapid eye movement (REM) sleep and recur 3 ± 5 times per sleep cycle. This amounts to 1.5 ± 3 h of potential oxygenation in the corpora cavernosa (6.3 ± 12.5% of a 24 h day compared to 22.5% in neonates). 14,15 These events in healthy men occur throughout their life span and gradually decline in frequency and duration with aging. 16 While the exact physiological function of NPT remains to be established, a lack of NPT is associated with ED. 2 One of the hypotheses discussed below proposes that NPT plays an important role in preservation of potency either in the structure or balance of metabolic factors maintaining tone in the corpora cavernosa. 2, 17 Penile structure determines erectile function Ð a functional trabecular smooth musclea connective tissue balance
The ®rst hypothesis of the pathophysiology of ED discussed here is based on the structural changes in the erectile apparatus affecting their function. The penis comprises soft tissue and functions as a blood®lled capacitor of suf®cient rigidity during erection for vaginal penetration. The two bodies of erectile tissue, the corpora cavernosa, that are integral to this function are composed of a specialized vascular bed which has a high content of connective tissue (48 ± 55%). The trabecular smooth muscle cells also synthesize connective tissue that contributes to the structural integrity of the corpora. In order to understand the pathophysiologic changes in ED, we carried out a prospective study on patients that were scheduled for penile prostheses implants who had dynamic infusion corpus cavernosometrya -ography (DICC) before the surgery. Biopsies removed at time of surgery were analyzed to determine the ratio of smooth muscle to connective tissue and the relationship of trabecular structure to function. Despite re-dosing during DICC, 17 patients with less than approximately 37% trabecular smooth muscle were more likely to have diffuse venous leakage. 16 A functional trabecular smooth muscleaconnective tissue ratio appears to be necessary for veno-occlusion. 16, 17 The implications of this ®nding are that, regardless of the amount of trabecular smooth muscle relaxation, veno-occlusion cannot occur in some patients due to higher content of connective tissue and an inability to occlude the draining venules. In the studies described above, despite repetitive dosing, 16, 18 patients with b 37% trabecular smooth muscle also had venous leakage.
Recently a`Process of Care' model has been developed for staging patients for ED pharmacotherapy. 19 With this treatment strategy, patients begin with oral or minimally invasive single agents and if these are not ef®cacious, injectable or intraurethral single-agent therapy is recommended. If this fails, bi and tri-mix injectable therapy will be tested. At present, the options for patients who fail injection therapy are limited and include surgical procedures such as penile prosthesis insertion. The failure rate of ED pharmacotherapy or the number of patients who seek surgical remediation is unknown at present.
One area of active research in erectile dysfunction is to identify vasoactive factors, cytokines, autacoids andaor neurotransmitters that may play a role in maintaining the connective tissueasmooth muscle balance. 2 Among the potential candidates are transforming growth factor b 1 (TGF-b 1 ) and prostaglandin E, both of which are synthesized by the trabecular smooth muscle cells. 2,16,20 ± 23 In a human corpus cavernosum smooth muscle cell in vitro model, these vasoactive substances were found to be regulated by oxygen tension TGF-b 1 is induced under lower oxygen tension conditions consistent with¯accidity while PGE is synthesized under conditions consistent with oxygen tensions during erection. 20 In the same model, TGF-b 1 can induce a 2.5 ± 4 fold increase in collagen synthesis in these cells and this synthesis can be repressed by a single dose of PGE 1 . 21 TGF-b 1 also auto-induces its own mRNA as well as the expression of both high-af®nity TGF-b receptors.
Since ED is associated with vascular risk factors such as diabetes, hypercholesterolemia and aging, and if structural changes underlie the pathophysiology of this condition, then animal models of disease should be in agreement with the in vitro tissue culture results. In rabbit animal models of disease with both hypercholesterolemia and diabetes, decreases in the smooth muscleaconnective tissue ratio in the corpus cavernosum are observed to correlate with increasing severity of disease. 2 In the case of hypercholesterolemia, an increase in constrictor prostanoids (PGF 2a and thromboxane A 2 ) and immunoreactive TGF-b were noted. Decreases in nitric oxide synthase-containing nerves and decreases in intracavernosal pressure upon pelvic nerve stimulation were found in a rat aging model. This correlated with trabecular structural changes and decreases in the smooth muscle content with age. 23 In a rabbit animal model, it has been demonstrated that time-released, intracorporal TGF-b 1 is suf®cient to induce diffuse corpus cavernosum ®brosis. 22 In a dog model of venoocclusive priapism, one of the ®rst cytokines to be induced post-injury is TGF-b 1 . 24 Taken together, data from cell culture and animal models suggests that there may be a role for TGF-b 1 and PGE in the pathophysiology of ED. This is not to suggest that these are the only factors. How other growth factors such as vascular endothelial growth factor (VEGF), nerve growth factor or nitric oxide affect gene expression and the subsequent balance of trabecular structure remains unknown. The transcriptionala post-transcriptional effects of vasoactive factors on other genes were illustrated in a recent study in rats, which found that repeated intracorporal PGE 1 injections up-regulated nitric oxide synthase expression in the penis. There is still much research required to clarify the role of various vasoactive factors on the transcriptional and translational regulation of gene products that in turn affect the structure and function of the corpora cavernosa.
In discussing the impact of these ®ndings on normal penile physiology, it is interesting to note that nocturnal penile tumescence 2,16,20 may provide a daily oxygenation of the corpus cavernosum, regardless of sexual activity, which may help to maintain a functional trabecular smooth musclea connective tissue balance. What clinical correlates exist to the importance of NPT or erections and potency? Erectile dysfunction has been reported in patients in which REM sleep and NPT are absent (sleep apnea) or disrupted (narcolepsy and epilepsy). 12 Of particular interest is one study in which one-third of the patients with sleep apnea and erectile dysfunction, continuous positive airway pressure improved erectile function as well as nocturnal penile tumescence. While further studies are needed, it appears that`erections may be good for preserving erections'. This type of rationale has been used in the treatment of nerve-sparing radical retropubic prostatectomy patients with PGE 1 intracavernosal injection post-operatively. 26 Montorsi found that under these circumstances, 67% of patients improved or recovered erectile function compared to 20% in the untreated group. 26 This study might predict a strong argument for`prophylaxis and prevention' of ED or predict the potential reversal of mild cases.
Intracavernosal injections of vasoactive agents, including PGE 1 , might be expected to reverse or cure' ED. In a retrospective examination of the literature, there was no convincing evidence of reversal of ED with intracavernosal injection. 27 Further, a recent limited prospective trial of 10 patients demonstrated that, while PGE 1 did not reverse trabecular structural changes in men undergoing injection therapy, their condition did not worsen. 28 While research has yet to supply an answer to a number of the questions involved, therapeutic strategies to alter the trabecular structure could be a future means to treat erectile dysfunction.
Dysfunctional antagonism' as the cause of ED
In this hypothesis, the cause of erectile dysfunction is proposed to be a metabolic imbalance between contractile and relaxatory factors in the corpus cavernosum. 3, 29 With functional antagonism, under normal physiologic conditions in the penis, contractile factors (norepinephrine, endothelin and contractile prostanoids) are in balance with relaxatory factors (nitric oxide, VIP) such that when contractile inhibition is released and relaxatory factors are present, erection ensues. In the case of dysfunctional antagonism, contractile factors predominate, are over-expressed or relaxatory factors are inhibited, such that the trabecular smooth muscle remains contracted and the penis¯accid. This is based on the observed strong central nervous system-mediated adrenergic inhibition of penile erection arising in part from the locus caeruleus. Some of the ®rst speculations on the molecular pathology of ED were based on increased adrenergic tone and decreased relaxatory potential in tissue from impotent men present for penile prosthesis insertions. 30 In other studies, attenuation of nitric oxide responses (NANC and endothelial) were reported and con®rmed in both human and animal models of diabetes, 31 as well as an animal model of hypercholesterolemia and ischemia. 32 Changes observed during aging were proposed to be a consequence of loss of relaxatory components (eg NO). 24 Gene transfer experiments with nitric oxide synthase in aged rats showed improved intracavernosal pressure in pelvic nerve-stimulated animals. 33,34 Gene therapy with maxi-K channels in aging rats also suggests that metabolic defects once corrected can improve erectile function. 35 Thus, this hypothesis predicts that, irrespective of trabecular structure, if the smooth muscle will relax upon delivery of appropriate agents, erection will occur.
Impact of pathophysiology of ED pharmacotherapeutics
The focus of pharmacotherapeutics in the last two decades has been a goal-oriented approach; that is, vasodilation is accomplished in the penis either by direct action of smooth muscle relaxants such as papaverine, PGE 1 or phentolamine, or by indirect means which enhance or amplify endogenous physiological pathways (eg sildena®l attenuation of the NO pathway). Multiple pharmacotherapies, which work by maximizing different smooth muscle pathways, have allowed ef®cacy by synergistically relaxing the smooth muscle. The recent report of an effective combination therapy of both MUSE TM (intraurethral PGE 1 ) and Viagra TM in patients who failed each individual therapy 36 suggests that activation of the cAMP-dependent pathway may work synergistically with the endogenous cGMPdependent pathway during the onset of penile erection. In all of these multiple drug therapies, the trabecular smooth muscle is made to relax maximally such that veno-occlusion occurs. If the structural hypothesis is correct, it would predict that, once patients pass the`point of no return' structurally, regardless of the therapy, the only treatments lie in surgical remediation (eg penile implants) or in a yet-to-be described therapy which permits remodeling of the connective tissue. In this case, ®nding a means to alter trabecular structure becomes a focus in an effort to restore potency.
However, if the metabolic hypothesis is correct, then all patients are treatable, regardless of etiology, and gene therapy is the ultimate goal of ED pharmacotherapy. By simply altering the balance of relaxatory factors in excess of the endogenous contractile ones, erection should ensue. What evidence exists for this hypothesis? In the`Process of Care' approach to treating ED as well as other treatment paradigms, patients are`staged' with single agents, then multiple treatments (bi-mix and tri-mix) and even four drug mixtures. However, there are some patients who are refractory to maximal dosing with several agents (tri-mix and quad-mix). Even re-dosing patients with lower ratios of smooth muscle to connective tissue failed to result in veno-occlusion. 16, 18 With the advent of more effective oral pharmacotherapy, it will be interesting to note what proportion of patients that are treated for ED have penile prostheses as a result of failure of other options.
Working hypothesis and future studies
Penile function is a balance between contractile and relaxatory factors as well as a functional smooth muscleaconnective tissue balance (Figure 1, Table  1 ). Shifting the balance may occur with normal aging, and appears to be accelerated by peripheral vascular disease, particularly diabetes, hypertension and hypercholesterolemia. The challenge of pharmacotherapeutics is to devise treatments that will overcome the imbalances of vaso-constrictors or structural constraints of diseased corpus cavernosum by either altering smooth muscle tone andaor modulating the smooth muscleaconnective tissue ratio. This will require basic science studies to understand the interplay of vasoactive and vasoconstrictive pathways, their impact on smooth muscle gene expression and the ultimate result on trabecular health. Clinically, noninvasive diagnostic tests that allow determination of the expandability of the corpora will aid in the screening of patients with regard to a`functional trabecular smooth muscleaconnective tissue ratio'. The pioneering work of Udelson 7,37 is a step in the right direction but needs to be modi®ed for clinical use. Depressed patients, once their symptoms are treated, can regain NPT as well as erectile function. 38 If this study can be repeated and veri®ed in a larger patient cohort, then the pathophysiologic differences between this psychogenic condition and vasculogenic ED will be de®ned and may shed light on the overall pathophysiology of ED. Other research questions to consider are the following: how is REM sleep related with NPT and why is NPT so important for the preservation of potency? If the structural hypothesis is correct, given connective tissue remodeling in other organs of the body, is ED reversible? Erectile dysfunction might be thought of as a progressive pelvic ischemia in the pelvic vascular tree, 37 and, if this is true, then does peripheral vascular disease accelerate the effects of normal aging? What are the effects of`normal aging' and how much of ED observed in epidemiology studies, such as the Massachusetts Male Aging Study, is due to vascular disease rather than aging?
As the`baby boom' generation ages and desires sexual ful®llment as part of the overall quality of life, there is a need for studies such as that of Martin, 39 which examined sexual frequencies in couples 65-y-old and older who where married 25 y or more. In this study, the group that remained sexually active throughout their lives was active during advanced age. With regard to the treatment of men whose corpora cavernosa have structural alterations to the point that all therapies fail, there is ), the trabecular smooth muscle of the lacunar spaces contracted. It is our hypothesis that these conditions favor the production of growth factors, cytokines and vasoactive factors, which favor connective tissue synthesis. During erection, corpus cavernosal blood PO 2 increases and plateaus at 90 ± 100 mmHg 1 and the trabecular smooth muscle of the lacunar spaces relaxes. We further hypothesize that these conditions favor connective tissue degradation. It is the sum of both processes which leads to the trabecular smooth muscleaconnective tissue balance (adapted with permission from Moreland.
2 (B) (Dys)functional antagonism: under normal physiological conditions, functional antagonism is in force such that contractile forces are balanced with relaxatory forces. When one or the other is in excess,¯accidity or erection occurs. With dysfunctional antagonism, the balance of factors is shifted to the contractile side either by decreased relaxatory responses andaor increased contractile factors (adapted with permission, from Melman and Gingell 3 and Montorsi et al 26 ). 40 It will be of interest to follow future developments in this area.
Conclusion
It is clear that both hypotheses of functional antagonism and a structural basis of ED play a role in an integrated molecular pathology of ED. The challenge awaiting researchers and clinicians is to understand the physiology and pathophysiology of ED so as to develop pharmacotherapeutics to treat a wide etiology of patients while addressing preservation of potency. Dr Christ: There is no literature available in corpus cavernosum per se that I'm aware of, but in smooth muscle in general, protein kinase C is thought to be part of the pathway that controls sensitization. There's dispute about that, depending upon which muscle type, but the kinase phosphorylates many proteins inside the cell. Some of those proteins are involved in transmembrane calcium¯ux and some have shown that activation of protein kinase C can decrease activity of K channels and increase activity of Ca 2 channels that would, in turn, increase intracellular Ca 2 . The Ca 2 ± calmodulin pathway can also be shifted to a point where lower intracellular Ca 2 levels can be maintained but the level of contractility will be higher. The pathway would work on the tonic portion of the contractile response where you're modulating the ef®ciency of the actin ± myosin interaction. Dr Heaton: In the psychogenically impotent male, there may be neither a pre-dilatory signal nor a resting vasoconstrictive stimulus; they're just in neutral, whereas in the endothelially damaged individual, vasoconstrictive activity is geared-up, producing much regulation; completely different situation.
Dr Moreland: Do depressed patients who have a decline in NPT end up with irreversible ED? Some of this data would predict that, but there are reports that say not. Is it because the vascular damage causes other paracrine and autocrine effects?
Dr Nehra: We see a number of young patients in our outpatient clinic with primary ED, non-psychogenics, who say they've never really had normal erections. Hormonal testing is normal and psychologically, they're okay. Do you have evidence that there may be some a-overactivity in these patients?
Dr Andersson: Any person who has a congenital de®ciency lacking the type I cGMP protein kinase should be impotent. There may be other links in the sequence leading to erection. It would be interesting to select patients resistant to sildena®l and ®nd out if they lack kinase activity. 
